facebook  linkedin xpix

Diary Dates
Save the date for important iCMLf meetings and programs

Become a member

Become an iCMLf member - help shape our future

Please donate

Support our activities
by donating
Donate here


We thank all our supporters and partners


If you are not a member, please click on "Register". If you have forgotten your password, please click on "Forgot login?" below.

Welcome to the iCMLf Virtual Education Program

This Virtual Education Program, provided by the iCMLf offers a series of webcast presentations from leading hematologists.

These presentations provide updated information on treatment advances and best practice management of CML, including disease monitoring and new therapies. The sessions specifically address issues of CML care in countries with limited access to monitoring and supplemental treatments.


Modules des langues français

Módulos en español


-- Virtual Education Program: 2016/17 Edition

We are pleased to make available a new series of presentations on modern diagnostics in CML that were first presented at the 'Clinical Symposium on Modern Diagnostics' during the 18th John Goldman Conference on CML in Houston in 2016. Modules currently featured include; The role of cytogenetic monitoring in CML management, Molecular monitoring in CML, Mutation screening and Biomarkers and response monitoring beyond PCR. 


Jorge Cortes 2013                          


The role of cytogenetic monitoring in CML management
Jorge Cortes - MD Anderson Cancer Center, University of Texas

  • Cytogenetic evaluation in CML
  • Cytogenetic clonal evolution
  • Additional chromosomal abnormalities in CML
  • Response to TKI by additional chromosomal abnormalities
  • Cytogenetic abnormalities in PH(1) metaphases
  • Additional cytogenetic abnormalities in CML-CP on TKI
  • Additional cytogenetic abnormalitites in 5q-MDS

Read more ...

Deborah White                                                                




Biomarkers and response monitoring beyond PCR?
Deborah White - SAHMRI, University of Adelaide

  • Predictive biomarkers
  • Cytokines, growth factors and chemokines: TGF and IL6
  • KIR2DS1 genotype and inferior cytogenetic response: SPIRIT1
  • CIP2A and response
  • Imatinib drug levels and compliance

Read more ...


 We are very grateful for the support of Brandcast media to produce this web stream
VEP Müller







Molecular monitoring in CML - getting to a safe place
Martin C. Müller, Institute for Hematology and Oncology (IHO) and Medical Faculty Mannheim, University of Heidelberg, Germany 

  • What do we consider safe?
  • Cytogenetic and molecular monitoring: European LeukemiaNet recommendations
  • Molecular monitoring every 3 months - enough for all patients?
  • Achieving deep remissions
  • Definitions of molecular response
  • Compliance check
  • Conclusions

Read more ...


 We are very grateful for the support of Brandcast media to produce this web stream
VEP Soverini







Mutation Screening:
What is standard of care today and the role of new modalities
Simona Soverini, University of Bologna, Italy 

  • BCR-ABL kinase domain (KD) mutation for optimal patient management
  • When to perform BCR-ABL KD mutation analysis
  • How to perform BCR-ABL KD mutation analysis
  • BCR-ABL KD mutation screening: key issues
  • Next-generation sequencing (NGS): applications
  • NGS for routine BCR-ABL mutatation testing: when?
  • NGS for routine BCR-ABL mutation screening: hurdles
  • Conclusions

Read more ...


VEP Mahon 





Stopping TKI therapy in Chronic Myeloid Leukemia
Francois-Xavier Mahon, Hospital University of Bordeaux, France 

  • What are the criteria for stopping treatment?
  • What is the definition of molecular relapse triggering re-treatment?
  • Is it safe to stop treatment?
  • Can we cure CML?

Read more ...